Phase 2 N=44 Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
Chronic Graft Versus Host Disease
Primary: Maximum Tolerated Dose of Ofatumumab — 1000 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=159 Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Recurrent Prostate Carcinoma · Stage IV Prostate Cancer AJCC v7
Primary: Confirmed Prostate-specific Antigen (PSA) Response Rate — 46; 55 Participants — p=0.27
Phase 2 N=29 Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) in Study Participants — 46 percentage of participants
Phase 2 N=172 PI-88 in Hepatocellular Carcinoma After Hepatectomy
Carcinoma, Hepatocellular
Primary: Tumour Non-recurrence Rate — 32; 40; 35 Participants — p=0.072
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
Phase 2 N=200 A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine
Respiratory Disorders
Primary: Number of Subjects Reported With Each Solicited Local Adverse Event (AE) (Any and Grade 3) Within Each Vaccination Schedule — 64; 64; 2; 1 Participants
Phase 2 N=65 Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Lymphoma
Primary: Overall Survival — 32; 33 Participants
Phase 2 N=12 A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
End Stage Renal Disease
Primary: Anti-Xa Activity as Measured by the AUC (Area Under the Curve) 0-t — .798; .733 IU*hr/mL
Phase 2 N=491 Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
Stress Urinary Incontinence
Primary: Number of Participants With a ≥ 50% Reduction From Baseline in the Mean Number of Stress Incontinence Episodes Per Day at Week 12 — 94; 96; 87 Participants
Phase 2 N=18 Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
Ovarian Neoplasms Malignant (Excl Germ Cell) · Peritoneal Carcinoma · Fallopian Tube Cancer
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Phase 2 N=415 Tolperisone in Acute Muscle Spasm of the Back
Back Pain · Acute Pain · Back Spasm Upper Back
Primary: Mean Effect Size in Subjected-Rated Pain — -4.2; -4.0; -3.7; -4.4 score on a scale
Phase 2 N=8 Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Urothelial Carcinoma · Bladder Cancer · Urinary Bladder Neoplasms
Primary: Percentage of Participants Who Enrolled and Underwent a Biopsy Who Went on to Receive Treatment Within 21 Days — 63 percentage of participants
Phase 2 N=134 Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
Atrial Fibrillation
Primary: Atrial Fibrillation Burden (AFB) at Baseline — 12.7; 10.8; 11.6; 11.7 Percentage of total recording time
Phase 2 N=108 A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
Prostate Cancer
Primary: Part 2: Percentage of Participants With Objective Tumor Response (Response Rate) — 15.2; 15.0 percentage of participants — p=1.0000
Phase 2 N=23 Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Number of Patients With Treatment-Emergent Adverse Events (AEs) — 4; 11 Participants